F. Costa

发表

RESILIENCE: Phase III Randomized, Double‐Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2‐Negative Breast Cancer

J. Bergh, C. Hudis, W. Gradishar, 2017, Clinical breast cancer.

Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.

M. Espié, J. Baselga, P. Hoff, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mitoxantrone, folinic acid, 5-fluorouracil and prednisone as first-line chemotherapy for advanced breast carcinoma. A phase II study.

F. Costa, J. Carmo-Pereira, E. Henriques, 1993, European journal of cancer.

Primary chemotherapy with mitoxantrone and prednisone in advanced breast carcinoma. A phase II study.

F. Costa, F. Godinho, J. Carmo-Pereira, 1988, European journal of cancer & clinical oncology.

High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study

D. Miles, R. Rubens, M. Richards, 2004, Cancer Chemotherapy and Pharmacology.

LBA8A PHASE III RANDOMIZED, DOUBLE-BLIND, TRIAL COMPARING SORAFENIB PLUS CAPECITABINE VERSUS PLACEBO PLUS CAPECITABINE IN THE TREATMENT OF LOCALLY ADVANCED OR METASTATIC HER2-NEGATIVE BREAST CANCER (RESILIENCE)

J. Bergh, C. Hudis, W. Gradishar, 2014 .

Single-Drug vs Combination Chemotherapy an Advanced A Randomized Study* Cytotoxic Breast Cancer:

F. Costa, E. Henriques, Cllnica Oncolbgica Viii, 1980 .

Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.

F. Costa, P. Pimentel, J. Carmo-Pereira, 1980, Cancer treatment reports.

A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.

R. Rubens, F. Costa, F. Godinho, 1987, British Journal of Cancer.

Single-drug vs combination cytotoxic chemotherapy in advanced breast cancer: a randomized study.

F. Costa, J. Carmo-Pereira, E. Henriques, 1980, European journal of cancer.

Moderate-dose cyclophosphamide for disseminated ovarian carcinoma: a phase II study.

F. Costa, J. Carmo-Pereira, E. Henriques, 1983, European journal of cancer & clinical oncology.

Advanced ovarian carcinoma: A prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa‐CAF)

F. Costa, J. Carmo-Pereira, E. Henriques, 1981, Cancer.

Chemotherapy of advanced breast cancer: A randomized trial of vincristine, adriamycin, and cyclophosphamide (VAC) versus cyclophosphamide, methotrexate, 5‐fluorouracil, and prednisone (CMFP)

F. Costa, J. Carmo-Pereira, E. Henriques, 1981, Cancer.

A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial

C. Hudis, W. Gradishar, J. Baselga, 2013, Trials.

Systemic treatment in patients with Child–Pugh B liver dysfunction and advanced hepatocellular carcinoma

G. Abou-Alfa, B. Wiedenmann, C. Roderburg, 2023, Cancer medicine.

Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.

F. Costa, J. Carmo-Pereira, E. Henriques, 1984, Cancer treatment reports.

5-fluorouracil, epirubicin and cyclophosphamide, as first-line cytotoxic chemotherapy for disseminated breast carcinoma. A phase II study

F. Costa, J. Carmo-Pereira, E. Henriques, 1995 .